Incannex Healthcare (NASDAQ:IXHL) and Cronos Group (NASDAQ:CRON) Financial Contrast

Cronos Group (NASDAQ:CRON) and Incannex Healthcare (NASDAQ:IXHL) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation and analyst recommendations.

Analyst Recommendations

This is a summary of current recommendations and price targets for Cronos Group and Incannex Healthcare, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cronos Group	1	2	2	0	2.20
Incannex Healthcare	1	0	0	0	1.00

Cronos Group currently has a consensus price target of $2.30, indicating a potential downside of 14.18%. Given Cronos Group’s stronger consensus rating and higher probable upside, equities analysts plainly believe Cronos Group is more favorable than Incannex Healthcare.

Profitability

This table compares Cronos Group and Incannex Healthcare’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cronos Group	-6.44%	-1.12%	-1.07%
Incannex Healthcare	N/A	-114.95%	-103.38%

Earnings & Valuation

This table compares Cronos Group and Incannex Healthcare”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cronos Group	$146.59 million	6.88	-$9.45 million	($0.01)	-268.00
Incannex Healthcare	N/A	N/A	-$46.88 million	($8.41)	-0.48

Cronos Group has higher revenue and earnings than Incannex Healthcare. Cronos Group is trading at a lower price-to-earnings ratio than Incannex Healthcare, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

8.7% of Cronos Group shares are held by institutional investors. Comparatively, 0.4% of Incannex Healthcare shares are held by institutional investors. 7.3% of Cronos Group shares are held by insiders. Comparatively, 1.3% of Incannex Healthcare shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk and Volatility

Cronos Group has a beta of 0.81, suggesting that its stock price is 19% less volatile than the S&P 500. Comparatively, Incannex Healthcare has a beta of 7.5, suggesting that its stock price is 650% more volatile than the S&P 500.

Summary

Cronos Group beats Incannex Healthcare on 10 of the 13 factors compared between the two stocks.

About Cronos Group

Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.

About Incannex Healthcare

Incannex Healthcare Inc., a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies. It develops products for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, pain, and other indications. The company offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. It also develops IHL-42X, which has completed Phase IIb clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 skin that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis. In addition, its product portfolio includes IHL-675A for inflammatory lung disease, IHL-675A for rheumatoid arthritis, IHL-675A for inflammatory bowel disease, and IHL-216A for traumatic brain injury and concussion, which have completed pre-clinical trials; and MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpatic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for chrohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for addiction of cannabis, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, suppoCan gastro for IBD, and APIRx-1702 for dry eye syndrome that are in pre-clinical trials. Incannex Healthcare Inc. was incorporated in 2001 and is based in Sydney, Australia.